Symptoms of nerve compression by meningioma

Update Date: Source: Network

summary

Meningioma is very common, accounting for 15.31% of intracranial tumors, second only to glioma. More adults, less elderly and children, fewer infants. Women are slightly more than men. It is a benign tumor occurring in meningeal cells and also an important tumor in orbit. Because of its high incidence rate, serious damage to vision, wide range of invasion, easy to spread to bone tube, bone fissures and bone walls. After surgery, recurrence and death are often recurred. Ophthalmologists and neurologist attach great importance to it. It is worth noting that it is difficult to determine the primary location of some tumors. Meningioma nerve compression symptoms to talk to you

Symptoms of nerve compression by meningioma

The clinical manifestations of primary meningiomas in orbit are different due to different locations. Even if the tumor occurs in the optic nerve sheath, the primary symptoms in the tube or orbit are not the same. Tumors in the optic nerve sheath usually have two growth forms. One form is tumor cell proliferation and invasion of sheath space, pia mater and dura mater, but dura mater is not penetrated, the surface remains intact, the tumor develops to eyeball and intracranial direction, the shape is tubular thickening. The other is that the tumor breaks through the dura mater in the early stage, that is, it develops along the longitudinal axis of the optic nerve, grows around the optic nerve or to one side, and its shape is fusiform or massive. When the tumor grows and is limited by the orbital wall, it forms a cone-shaped mass consistent with the orbital cavity. Periosteal tumors grow along the periosteum and do not affect the optic nerve in the early stage.

The most common and early sign of intraorbital meningioma is exophthalmos, which is found in more than 95% of cases. Especially for the tumors that break through the meninges to the optic nerve or grow around the optic nerve in the early stage, and the tumors that originate outside the optic nerve sheath, exophthalmos is the first sign to attract the attention of patients. The direction of exophthalmos generally develops forward along the ocular axis. The primary tumor in the greater pterygoid periosteum often makes the eyeball move inward and downward. The degree of exophthalmos varies from person to person. The tumor originated from or developed along the optic nerve sheath in the optic nerve canal. The degree of exophthalmos was low and even spread in the brain. The degree of exophthalmos was only 2-3 mm. The tumor occurred in the orbit and showed massive growth. The exophthalmos was obvious, and the difference between the two sides was more than 20 mm. In severe cases, the eyeball was detached from the palpebral fissure.

Severe vision loss is also one of the early symptoms. More than 50% of the newly diagnosed patients had visual acuity lower than 0.1. The loss of vision is related to the primary site of the tumor. In the optic canal, vision loss and vision loss are often the only symptoms in the early stage. Only a few patients have headache, and there is no exophthalmos for a long time. In the early stage, they are often misdiagnosed as retrobulbar optic neuritis. The tubular meningioma developed along the optic nerve sheath, atrophied due to the compression of optic nerve fibers, lost vision earlier, and the exophthalmos was not obvious. Only those meningiomas that break through the dura mater of the optic nerve in the early stage, develop to one side, or originate outside the optic nerve sheath, will have vision loss in the late stage. In the early stage of tubular meningioma, the visual field shrinks, and if it occurs in the orbital apex, there may be dark spots in the visual field.

matters needing attention

The average survival time of meningiomas was 9 years. The 10-year survival rate of meningiomas was 43% - 78%. Meningioma is a kind of benign tumor, and its recurrence in situ is noticeable. It is very important to improve the surgical grade to reduce the recurrence rate.